{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T02:11:35Z","timestamp":1792980695871,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","annemergmed.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Emergency Medicine"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.annemergmed.2018.04.019","type":"journal-article","created":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T02:51:14Z","timestamp":1528167074000},"page":"79-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Adverse Effects of Immune Checkpoint Therapy in Cancer Patients Visiting the Emergency Department of a Comprehensive Cancer Center"],"prefix":"10.1016","volume":"73","author":[{"given":"Imad","family":"El Majzoub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiham","family":"Qdaisat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyaw Z.","family":"Thein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myint A.","family":"Win","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myat M.","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalen","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick S.","family":"Chaftari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Prejean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cielito","family":"Reyes-Gibby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5170-0822","authenticated-orcid":false,"given":"Sai-Ching J.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annemergmed.2018.04.019_bib1","article-title":"Emerging targets in cancer immunotherapy","author":"Burugu","year":"2017","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00262-017-1954-6","article-title":"PD-1 and PD-L1 antibodies in cancer: current status and future directions","volume":"66","author":"Balar","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.pharmthera.2017.07.004","article-title":"Oncogenic pathways that affect antitumor immune response and immune checkpoint blockade therapy","volume":"181","author":"Zhao","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib4","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1158\/0008-5472.CAN-16-2379","article-title":"Intrinsic resistance of solid tumors to immune checkpoint blockade therapy","volume":"77","author":"Zhao","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/cei.13081","article-title":"Immune checkpoint inhibitors: new strategies to checkmate cancer","volume":"191","author":"Wilson","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib6","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","article-title":"Radiotherapy and immunotherapy: a beneficial liaison?","volume":"14","author":"Weichselbaum","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib7","doi-asserted-by":"crossref","first-page":"20170157","DOI":"10.1259\/bjr.20170157","article-title":"Combining radiotherapy with immunotherapy: the past, the present and the future","volume":"90","author":"Van Limbergen","year":"2017","journal-title":"Br J Radiol"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib8","article-title":"Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy","author":"Rotte","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib10","unstructured":"National Cancer Institute. Ipilimumab. Available at: https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/ipilimumab. Accessed March 16,\u00a02018."},{"key":"10.1016\/j.annemergmed.2018.04.019_bib11","unstructured":"National Cancer Institute. Nivolumab. Available at: https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/Nivolumab. Accessed March 16,\u00a02018."},{"key":"10.1016\/j.annemergmed.2018.04.019_bib12","unstructured":"National Cancer Institute. Pembrolizumab. Available at: https:\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/pembrolizumab. Accessed March 16,\u00a02018."},{"key":"10.1016\/j.annemergmed.2018.04.019_bib13","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2017.77.0446","article-title":"Clinical cancer advances 2018: annual report on progress against cancer from the American Society of Clinical Oncology","volume":"36","author":"Heymach","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib14","doi-asserted-by":"crossref","DOI":"10.14694\/EdBook_AM.2015.35.76","article-title":"Managing immune checkpoint-blocking antibody side effects","author":"Postow","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib15","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review","volume":"2","author":"Friedman","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib16","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib19","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib22","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.2147\/OTT.S97903","article-title":"Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives","volume":"10","author":"Feld","year":"2017","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pharmthera.2017.07.005","article-title":"Toxicity profiles of immunotherapy","volume":"181","author":"Cousin","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib24","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management","volume":"58","author":"Sznol","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib25","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.annemergmed.2016.03.048","article-title":"Pituitary dysfunction: a case series of immune checkpoint inhibitor\u2013related hypophysitis in an emergency department","volume":"68","author":"Miller","year":"2016","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib26","doi-asserted-by":"crossref","first-page":"1039.e1035","DOI":"10.1016\/j.ajem.2017.02.048","article-title":"Acute symptomatic hypocalcemia from immune checkpoint therapy\u2013induced hypoparathyroidism","volume":"35","author":"Win","year":"2017","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib27","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/1556-4029.13633","article-title":"Fatal myocarditis following treatment with the PD-1 inhibitor nivolumab","volume":"63","author":"Matson","year":"2017","journal-title":"J\u00a0Forensic Sci"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib28","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1200\/JCO.2010.34.2816","article-title":"Why do patients with cancer visit emergency departments? results of a 2008 population study in North Carolina","volume":"29","author":"Mayer","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib29","doi-asserted-by":"crossref","first-page":"e0191658","DOI":"10.1371\/journal.pone.0191658","article-title":"Oncologic emergencies in a cancer center emergency department and in general emergency departments countywide and nationwide","volume":"13","author":"Yang","year":"2018","journal-title":"PLOS One"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib30","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/1742-6723.12718","article-title":"Acute management of autoimmune toxicity in cancer patients on immunotherapy: common toxicities and the approach for the emergency physician","volume":"29","author":"Lomax","year":"2017","journal-title":"Emerg Med Australas"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib31","doi-asserted-by":"crossref","first-page":"W992","DOI":"10.2214\/AJR.10.6198","article-title":"Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy","volume":"197","author":"Bronstein","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib32","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.urolonc.2017.08.005","article-title":"PD-1 checkpoint inhibition: toxicities and management","volume":"35","author":"Hahn","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib33","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib34","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.3892\/ol.2015.4069","article-title":"Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma","volume":"11","author":"Khoja","year":"2016","journal-title":"Oncol Lett"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib35","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1200\/JCO.2016.72.1167","article-title":"Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma","volume":"35","author":"Sznol","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib36","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","author":"Faje","year":"2016","journal-title":"Pituitary"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib37","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/ijc.30678","article-title":"Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis of published data","volume":"141","author":"Wang","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib38","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejim.2017.08.019","article-title":"Cancer immunotherapy-induced endocrinopathies: clinical behavior and therapeutic approach","volume":"47","author":"Iglesias","year":"2017","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib39","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40425-018-0321-2","article-title":"Ipilimumab induced digital vasculitis","volume":"6","author":"Padda","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-216228","article-title":"Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer","author":"Gibson","year":"2016","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40425-015-0057-1","article-title":"Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma","volume":"3","author":"Laubli","year":"2015","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib42","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/1752-1947-8-240","article-title":"Serious haematological toxicity during and after ipilimumab treatment: a case series","volume":"8","author":"Simeone","year":"2014","journal-title":"J\u00a0Med Case Rep"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib43","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.soncn.2017.08.003","article-title":"Cancer therapy with checkpoint inhibitors: establishing a role for ophthalmology","volume":"33","author":"Davis","year":"2017","journal-title":"Semin Oncol Nurs"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib44","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib45","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","author":"Brahmer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annemergmed.2018.04.019_bib46","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center","volume":"33","author":"Horvat","year":"2015","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Annals of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196064418303640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196064418303640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T03:19:51Z","timestamp":1604373591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196064418303640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0196064418303640"],"URL":"https:\/\/doi.org\/10.1016\/j.annemergmed.2018.04.019","relation":{},"ISSN":["0196-0644"],"issn-type":[{"value":"0196-0644","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse Effects of Immune Checkpoint Therapy in Cancer Patients Visiting the Emergency Department of a Comprehensive Cancer Center","name":"articletitle","label":"Article Title"},{"value":"Annals of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annemergmed.2018.04.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American College of Emergency Physicians.","name":"copyright","label":"Copyright"}]}}